12.1 Malignant Hyperthermia: Presentation, Ryanodex/Dantrolene Protocol & ASC Preparedness

Malignant Hyperthermia: Presentation, Ryanodex/Dantrolene Protocol & ASC Preparedness

Core Principle: Malignant Hyperthermia (MH) is a fulminant, pharmacogenetic hypermetabolic crisis of skeletal muscle triggered by volatile halogenated anesthetics or succinylcholine. In freestanding ambulatory surgery centers (ASCs), where specialized code teams and critical care units do not exist on-site, the perioperative nurse's ability to instantly recognize early non-thermal warning signs and execute the MHAUS emergency treatment protocol within minutes is the definitive factor separating patient survival from fatal cardiovascular collapse.

---

Pathophysiology & Genetics of Malignant Hyperthermia

Malignant Hyperthermia is inherited as an autosomal dominant trait with variable penetrance and expressivity. Approximately 70% to 80% of susceptible individuals harbor mutations in the RYR1 gene (ryanodine receptor type 1), located on chromosome 19q13.1, which encodes the principal calcium-release channel in the skeletal muscle sarcoplasmic reticulum (SR). A smaller subset of individuals possesses mutations in the CACNA1S gene, encoding the alpha-1S subunit of the voltage-dependent L-type calcium channel (dihydropyridine receptor) on the transverse tubule (T-tubule).

The Hypermetabolic Cascade

1. Uncontrolled Sarcoplasmic Calcium Influx: Upon exposure to a triggering agent, defective ryanodine channels lock open, causing an uncontrolled, massive efflux of stored calcium (Ca²⁺) from the sarcoplasmic reticulum into the skeletal muscle myoplasm.
2. Sustained Actin-Myosin Cross-Bridging: Intracellular calcium saturation prevents troponin from inhibiting tropomyosin, locking actin and myosin into relentless, uninhibited cross-bridging and muscle contraction.
3. ATP Depletion & Hypermetabolism: Muscle cells desperately attempt to sequester excess calcium back into the SR via calcium ATPase pumps and restore cellular homeostasis. This consumes massive quantities of adenosine triphosphate (ATP), stimulating aerobic and anaerobic glycolysis, cellular oxygen consumption (VO₂), and carbon dioxide production (VCO₂) by two to five times baseline levels.
4. Rhabdomyolysis & Sarcolemmal Rupture: Cellular energy starvation leads to hyperthermia (heat produced as a byproduct of uncontrolled ATP breakdown), severe lactic and respiratory acidosis, and failure of cellular membrane integrity. Muscle fibers rupture (rhabdomyolysis), releasing toxic intracellular contents—potassium (K⁺), creatine kinase (CK), and myoglobin—into systemic circulation.

---

Triggering vs. Safe Non-Triggering Anesthetic Agents

The ambulatory perioperative team must distinguish between known triggering pharmacological agents and safe alternatives for known MH-susceptible (MHS) patients or family members.

---

Clinical Presentation & Timeline of Symptoms

Malignant Hyperthermia is insidious and dynamic. It can manifest immediately upon induction, intraoperatively during maintenance, or up to several hours postoperatively in the Phase I PACU. Recognition depends on understanding the chronological sequence of physiological decompensation.

┌────────────────────────────────────────────────────────────────────────┐
│               CHRONOLOGICAL SPECTRUM OF MH MANIFESTATIONS              │
├────────────────────────────────────────────────────────────────────────┤
│ [EARLIEST]  ↳ Hypercarbia (EtCO2 doubling/tripling, refractory)        │
│             ↳ Unexplained sinus tachycardia & tachypnea                 │
│ [EARLY]     ↳ Masseter Muscle Rigidity (MMR / "jaws of steel")          │
│             ↳ Generalized skeletal muscle rigidity                     │
│             ↳ Skin mottling, cyanosis, and profuse diaphoresis         │
│ [DEVELOPING]↳ Mixed metabolic and respiratory acidosis (pH <7.15)      │
│             ↳ Hyperkalemia (peaked T waves, ventricular ectopy)         │
│ [LATE]      ↳ Hyperthermia (>38.8°C / 101.8°F up to >42°C / 108°F)      │
│             ↳ Gross rhabdomyolysis: Cola-colored urine (myoglobinuria) │
│             ↳ Massive CK elevation (>20,000 - 100,000+ IU/L)           │
│             ↳ Disseminated Intravascular Coagulation (DIC)             │
└────────────────────────────────────────────────────────────────────────┘

1. Earliest and Most Sensitive Signs

• Hypercarbia (Rapid, Disproportionate Rise in EtCO₂): The earliest, most reliable objective indicator of MH. The end-tidal carbon dioxide abruptly doubles or triples (rising rapidly to 60, 80, 100+ mmHg) despite aggressive attempts by the anesthesia provider to hyperventilate the patient (e.g., doubling minute ventilation from 6 L/min to 12 L/min). Soda lime absorbent cannisters turn purple almost instantly and become intensely hot to the touch due to extreme exothermic CO₂ absorption.
• Unexplained Sinus Tachycardia: Heart rate jumps significantly above baseline without surgical stimulation, light anesthesia, or hypovolemia.
• Tachypnea: In spontaneously breathing or sedated patients, rapid, labored breathing occurs in response to metabolic drive.

2. Muscle Rigidity & Masseter Spasm

• Masseter Muscle Rigidity (MMR / Trismus): Following succinylcholine administration during induction, jaw muscles clench tight ("jaws of steel"), rendering direct laryngoscopy and mouth opening physically impossible. While isolated mild jaw stiffness can occur with succinylcholine, intractable rigidity that prevents airway instrumentation is considered an MH crisis until proven otherwise in approximately 50% of cases.
• Generalized Muscle Rigidity: Skeletal muscles throughout the body become board-like, stiff, and unyielding, persisting despite administration of non-depolarizing paralytics (such as rocuronium).

3. Progressive Acidosis & Hyperkalemia

• Severe Mixed Acidosis: Arterial blood gas (ABG) analysis reveals profound metabolic lactic acidosis accompanied by respiratory acidosis (pH <7.10–7.20, base excess worse than -10 mEq/L, PaCO₂ >60–90 mmHg). Arterial and venous oxygen saturation drops dramatically as tissues rapidly consume oxygen.
• Hyperkalemia: Massive potassium release from damaged sarcolemma drives serum potassium to life-threatening levels (K⁺ >6.0–8.0 mEq/L). The electrocardiogram (ECG) shows tall, peaked T waves, widening QRS complexes, ventricular bigeminy, ventricular tachycardia, and cardiac arrest.

4. Late Signs: Hyperthermia & Rhabdomyolysis

• Hyperthermia is a LATE Sign: Core body temperature does not rise initially! When it does rise, it escalates catastrophically by 1°C to 2°C every 5 minutes, rapidly reaching 40°C to 42°C+ (104°F to 108°F+). Clinical Rule: Never wait for a temperature elevation to diagnose or treat Malignant Hyperthermia! Waiting for fever results in severe neurological injury and mortality.
• Rhabdomyolysis & Myoglobinuria: Myoglobin released into circulation filters through the glomeruli, turning urine dark brown, tea-colored, or "cola-colored." Serum creatine kinase (CK) peaks 12 to 24 hours post-crisis, often exceeding 20,000 to 100,000+ IU/L. Precipitation of myoglobin casts in renal tubules precipitates acute tubular necrosis and acute renal failure.

---

The MHAUS Emergency Treatment Protocol

The Malignant Hyperthermia Association of the United States (MHAUS) establishes a strict, time-critical sequence of life-saving interventions. The perioperative team must execute these actions simultaneously.

Step 1: Discontinue Triggers, Call for Help & Bring MH Cart

• Immediately stop volatile anesthetics and succinylcholine. Notify the surgeon to halt the surgical procedure immediately, close or pack wounds, and prepare for emergent stabilization.
• Call for help and sound the facility emergency alarm. Mobilize all available nurses, technicians, and anesthesia personnel. Bring the dedicated MH Emergency Cart directly into the operating room.

Step 2: Hyperventilate with 100% Oxygen & Apply Charcoal Filters

• Turn anesthetic vaporizers completely OFF.
• Hyperventilate the patient with 100% oxygen at maximum fresh gas flows (≥10 L/min) to blow off excess CO₂ and meet soaring cellular oxygen demands.
• Do NOT waste time changing the anesthesia circuit or machine! Immediately attach activated charcoal filters (Vapor-Clean) to both the inspiratory and expiratory limbs of the breathing circuit. These filters scrub trace volatile gases from the circuit within 60 to 90 seconds, maintaining volatile concentrations below 5 ppm.

Step 3: Administer Dantrolene Sodium Immediately

Dantrolene sodium is a hydantoin derivative that binds specifically to the RYR1 ryanodine receptor, inhibiting calcium release from the sarcoplasmic reticulum into the myoplasm. It uncouples the hypermetabolic crisis without affecting cardiac or smooth muscle contractility.

Comparison: Ryanodex vs. Generic Dantrolene (Dantrium / Revonto)

• Initial Dosing: Administer dantrolene 2.5 mg/kg IV push rapidly via large-bore intravenous access.
• Repeat Dosing: Repeat boluses of 1 to 2.5 mg/kg IV every 5 to 10 minutes until clinical signs abate (EtCO2 normalizes, tachycardia resolves, muscle rigidity softens, and temperature stabilizes).
• Maximum Dose: The standard initial ceiling is 10 mg/kg, but doses exceeding 20 mg/kg may be necessary in fulminant cases. If no response is observed after 10 mg/kg, alternative diagnoses (e.g., thyroid storm, sepsis, pheochromocytoma) must be urgently reconsidered.

Step 4: Treat Life-Threatening Hyperkalemia

Hyperkalemia (K⁺ >6.0 mEq/L) drives fatal ventricular arrhythmias and must be managed aggressively:

1. Membrane Stabilization: Administer Calcium Chloride 10% (10 mg/kg IV, up to 1,000 mg) or Calcium Gluconate 10% (30 mg/kg IV, up to 3,000 mg) to antagonize cardiac membrane excitability.
2. Intracellular Shift: Administer Regular Insulin 10 units IV combined with 50% Dextrose (D50W) 50 mL (25 grams) to drive potassium into cells. Check blood glucose every 15 minutes.
3. Alkalinization: Administer Sodium Bicarbonate (1–2 mEq/kg IV) to shift potassium intracellularly and buffer profound metabolic acidosis.
4. CRITICAL WARNING: Never administer Calcium Channel Blockers (e.g., Verapamil, Diltiazem) in Malignant Hyperthermia! The combination of dantrolene and calcium channel blockers causes catastrophic, refractory hyperkalemia and lethal myocardial depression.

Step 5: Active Patient Cooling Protocol

Active cooling must commence as soon as dantrolene is pushed, utilizing all available modalities:

• Infuse chilled normal saline (0.9% NaCl chilled to 4°C) intravenously at 1,000 mL every 30 minutes (up to 2,000 to 3,000 mL).
• Apply ice packs to areas of high vascularity: axillae, groin, lateral neck, and head.
• Perform cold saline body cavities lavage: nasogastric tube gastric lavage and urinary bladder irrigation via a three-way Foley catheter.
• CEASE COOLING THRESHOLD: Stop all active cooling measures when core body temperature reaches 38.0°C (100.4°F)! Continuing cooling below 38.0°C precipitates profound rebound hypothermia, shivering (which skyrockets oxygen demand), and coagulopathy.

Step 6: Maintain Renal Perfusion & Diuresis

To prevent acute tubular necrosis from myoglobinuria, insert an indwelling urinary catheter with an integrated temperature sensor:

• Target and maintain a robust urine output of >1 to 2 mL/kg/hr.
• Administer intravenous crystalloids, Mannitol (0.25 g/kg IV; note: Ryanodex contains 0.163 g mannitol per vial), and Furosemide (0.5 to 1.0 mg/kg IV) to flush myoglobin casts through renal tubules.
• Alkalinize the urine by maintaining systemic pH >7.20 with sodium bicarbonate, as alkaline urine prevents myoglobin crystallization in distal nephrons.

Step 7: Call the MHAUS 24-Hour Hotline

As soon as initial interventions are underway, designate a nurse to call the MHAUS Emergency Hotline: 1-800-644-9737 (1-800-MH-HYPER). An experienced, on-call anesthesiologist specializing in Malignant Hyperthermia will provide real-time, step-by-step clinical guidance, medication titration, and transfer consultation.

Step 8: Emergency Transfer to Inpatient Critical Care (ICU)

Freestanding ambulatory surgery centers cannot manage post-MH recovery. Once the patient is stabilized:

• Activate EMS 911 for emergent ALS transfer to an acute care hospital intensive care unit.
• Recrudescence Warning: Malignant Hyperthermia recurs (recrudescence) in 20% to 25% of cases within 24 to 36 hours of the primary event. Patients require continuous ICU invasive arterial pressure, core temperature, blood gas, and electrolyte monitoring, receiving maintenance dantrolene at 1 mg/kg IV every 4 to 6 hours for at least 24 hours, with further dosing and monitoring guided by MHAUS criteria and the patient’s course.